Trevena Initiates Dosing In Phase 2b BLAST-AHF Trial Of TRV027 For AHF Patients

(RTTNews) - Trevena, Inc., a clinical stage biopharmaceutical company involved in the discovery and development of G-protein coupled receptor or GPCR biased ligands, announced Thursday the initiation of dosing in BLAST-AHF, the company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure or AHF.

Trevena noted that the randomized, double-blind, standard of care controlled, Phase 2b BLAST-AHF trial is designed to enroll at least 500 patients with AHF, and will compare TRV027 plus standard heart failure therapy versus placebo plus standard therapy.

The primary objective of this trial is to evaluate the effects of three dose levels of TRV027, 1.0 mg/hr, 5.0 mg/hr and 25 mg/hr, on a composite of clinically important outcomes.

The company noted that TRV027 is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor that is being developed as a first-line intravenous treatment in combination with standard diuretic therapy for AHF patients. Trevena has granted Forest Laboratories (FRX) an exclusive option to license TRV027 under the companies' May 2013 Option and Licensing Agreements.

The company added that it looks forward to advancing the BLAST-AHF trial and expect data to be available in the second half of 2015.